Table S1 The formulas of inflammation-related indexes

Index	Formula
NLR	Neutrophil/lymphocyte
dNLR	(white blood cell - lymphocyte)/lymphocyte
PLR	Platelet/lymphocyte
LMR	Pymphocyte/monocyte
GPR	GGT/platelet (10 ⁹ /L)
SII	Platelet (10 ⁹ /L) × neutrophil/lymphocyte
PNI	Albumin + 5 × lymphocyte (10 ⁹ /L)
APRI	AST (U/L)/platelet (10 ⁹ /L)
ANRI	AST (U/L)/neutrophil (10 ⁹ /L)
ALRI	AST (U/L)/lymphocyte (10 ⁹ /L)
ALBI	$0.66 \times log_{10}$ (bilirubin) (µmol/L) $- 0.085 \times albumin$ (g/L)
FIB-4	[age (yr) \times AST (U/L)]/[platelet (10 9 /L) \times ALT(U/L) $^{1/2}$]
S-index	1000 × GGT/[platelet (10 ⁹ /L) × albumin (g/L) ²]

GGT: gamma-glutamyl transpeptidase; AST: aspartate transaminase; ALT: alanine transaminase; NLR: neutrophil-to-lymphocyte ratio; dNLR: derived neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; LMR: lymphocyte-to-monocyte ratio; GPR: gamma-glutamyl transpeptidase-to-platelet ratio; SII: systemic immune-inflammation index; PNI: prognostic nutritional index; APRI: aspartate transaminase-to-platelet count ratio index; ANRI: aspartate transaminase-to-neutrophil ratio index; ALRI: aspartate transaminase-to-lymphocyte ratio index; ALBI: albumin-bilirubin; FIB-4: fibrosis index based on the four factors.

Table S2 Different risk groups for overall, early, and late RFS according to the NomoScores

NomoSore Groups	Range	Cases (%)	1-year RFS	2-year RFS	3-year RFS	5-year RFS
Overall RFS						
Low risk	≤125	131 (34.2%)	77.9%	64.8%	60.4%	53.6%
Moderate risk	125–280	183 (47.8%)	57.4%	8.9%	27.7%	22.2%
High risk	>280	69 (18.0%)	29.9%	12.0%	6.0%	2.0%
Early RFS						
Low risk	≤222	209 (54.6%)	71.6%	57.4%		
Moderate risk	222–320	101 (26.4%)	54.6%	34.6%		
High risk	>320	73 (19.0%)	31.0%	12.2%		
Late RFS						
Low risk	≤100	98 (88.3%)			88.0%	77.2%
High risk	>100	13 (11.7%)			34.2%	0.0%

RFS: recurrence-free survival.




Figure S1 The cut-off point identification of the NomoScores for overall (A, B, and C), early (D, E, and F), and late (G, H, and I) RFS produced by X-tile plots. RFS: recurrence-free survival.